The Journal of Allergy and Clinical Immunology
Volume 116, Issue 3 , Pages 517-524 , September 2005

Efficacy and tolerability of antiasthma herbal medicine intervention in adult patients with moderate-severe allergic asthma

  • Ming-Chun Wen, MD

      Affiliations

    • From the Weifang Asthma Hospital
    • Corresponding Author InformationMing-Chun Wen, MD, Weifang Asthma Hospital, Weifang, N0. 68, Xinhua Road, Weifang, Shandong 261041, China.
    • ,
  • Chun-Hua Wei, MD

      Affiliations

    • From the Weifang Asthma Hospital
    • ,
  • Zhao-Qiu Hu, MD, MS

      Affiliations

    • From the Weifang Asthma Hospital
    • ,
  • Kamal Srivastava, MPhil

      Affiliations

    • Department of Pediatrics
    • ,
  • Jimmy Ko, MD

      Affiliations

    • Department of Pediatrics
    • ,
  • Su-Ting Xi, MD, MS

      Affiliations

    • From the Weifang Asthma Hospital
    • ,
  • Dong-Zhen Mu, MD, MS

      Affiliations

    • Department of Immunology, Weifang School of Medicine
    • ,
  • Ji-Bin Du, MD

      Affiliations

    • From the Weifang Asthma Hospital
    • ,
  • Guo-Hua Li, MD

      Affiliations

    • From the Weifang Asthma Hospital
    • ,
  • Sylvan Wallenstein, PhD

      Affiliations

    • Department of Community Medicine, Mount Sinai School of Medicine, New York
    • ,
  • Hugh Sampson, MD

      Affiliations

    • Department of Pediatrics
    • ,
  • Meyer Kattan, MD

      Affiliations

    • Department of Pediatrics
    • ,
  • Xiu-Min Li, MD

      Affiliations

    • Department of Pediatrics
    • Corresponding Author InformationReprint requests: Xiu-Min Li, MD, Pediatric Allergy and Immunology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574.

Received 20 January 2005 ,Revised 9 May 2005 ,Accepted 16 May 2005.

  • Image Result

    Effect of treatment with (A) ASHMI or (B) prednisone on symptom scores. Average daily symptom scores were evaluated over a 1-week period before treatment to establish a baseline (week 0). The effect o

    Effect of treatment with (A) ASHMI or (B) prednisone on symptom scores. Average daily symptom scores were evaluated over a 1-week period before treatment to establish a baseline (week 0). The effect of treatment on symptom scores was evaluated by analyzing average daily symptom scores in weeks 1, 2, 3, and 4 of treatment. ∗∗∗P < .001.

  • Image Result
    Effect of 4 weeks of treatment with ASHMI or prednisone on (A) FEV1, (B) PEF, or (C) β-agonist use. ∗∗∗P < .001.

    Effect of 4 weeks of treatment with ASHMI or prednisone on (A) FEV1, (B) PEF, or (C) β-agonist use. ∗∗∗P < .001.

  • Image Result
    Effect of 4 weeks of treatment with ASHMI or prednisone on eosinophil numbers in peripheral blood. ∗∗∗P < .001.

    Effect of 4 weeks of treatment with ASHMI or prednisone on eosinophil numbers in peripheral blood. ∗∗∗P < .001.

  • Image Result
    Effect of 4 weeks of treatment with ASHMI or prednisone on serum cortisol levels (7:30-8:30 AM) determined by radioimmunoassay. Data are means ± SDs. ∗∗∗P < .001.

    Effect of 4 weeks of treatment with ASHMI or prednisone on serum cortisol levels (7:30-8:30 AM) determined by radioimmunoassay. Data are means ± SDs. ∗∗∗P < .001.

  • Image Result
    Effect of 4 weeks of treatment with ASHMI or prednisone on (A) serum IgE titers, (B) IL-13, (C) IL-5, and (D) IFN-γ as determined by ELISA. Data are medians (A) or means ± SDs (B-D). ∗∗∗P < .001.

    Effect of 4 weeks of treatment with ASHMI or prednisone on (A) serum IgE titers, (B) IL-13, (C) IL-5, and (D) IFN-γ as determined by ELISA. Data are medians (A) or means ± SDs (B-D). ∗∗∗P < .001.

 Supported by National Institutes of Health grant # AT001495-01A1.Disclosure of potential conflict of interest: M.-C. Wen has filed a US patent application (reference #60554775). H. Sampson has received grants/research support from the National Institutes of Health and has filed a US patent application (reference #60554775). M. Kaltan is on the speakers' bureau for AstraZeneca. X.-M. Li has received grants/research support from the National Institutes of Health and has filed a US patent application (reference #60554775).

PII: S0091-6749(05)01358-8

doi: 10.1016/j.jaci.2005.05.029

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 3 , Pages 517-524 , September 2005

Article Tools

* Image Usage & Resolution